Please login to the form below

Ranbaxy

This page shows the latest Ranbaxy news and features for those working in and with pharma, biotech and healthcare.

Nearly half of all clinical trials not published

Drilling down into the data provides a mixed picture for the pharma industry - at one end of the scale is Ranbaxy, which has published no results for any of the 35

Latest news

Lundbeck challenge to EC pay-for-delay ruling fails

The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around 52m, and those judgments have also been upheld by the General Court of the EU.
India denies Vertex patent on cystic fibrosis drug Orkambi

The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
Heart drug sales continue downward spiral

The Swiss firm has managed to delay some generic forms of its drug onto the market until last year, when Ranbaxy was granted approval to sell its copycat form of valsartan.
Takeda to pay $2.4bn to settle Actos cancer suits

Actos has generated more than $16bn in sales since its 1999 release, according to court filings, but now also faces generic competition from India's Ranbaxy Laboratories.
Teva slapped with $512m fine on pay-for-delay deal

Ranbaxy Laboratories. ... Mylan and Ranbaxy, which are also defendants in the case, are not part of the settlement.

More from news
Approximately 7 fully matching, plus 107 partially matching documents found.

Latest Intelligence

Pharma deals in April 2015

The acquisition of this portfolio with sales of INR 150 Crores, will help Dr Reddy's maintain a competitive edge with fellow Indian rival Sun Pharmaceuticals, following its acquisition of Ranbaxy
Allergan and taking a specialised approach

But for the likes of GSK, Novartis and Lilly with their asset swap agreement, Forest Laboratories and its acquisition of Actavis, and the various dealings at Merck &Co, BMS, Ranbaxy and
Pharma deals during April 2014

The total cost of the all-stock acquisition is $4.0bn (an 18% premium), $3.2bn in stock and nearly $800m of Ranbaxy debt. ... Eclipsing all else will be restoring FDA confidence. To this end immediate remedial action will involve management restructuring
Deal Watch table for April 2014

Ranbaxy Laboratories/ Sun Pharmaceuticals. Acquisition. Generics including Lipitor, Nexium, Diovan. 3, 200.
Positive prospects for pharma in Latin America

Since 2008, more foreign companies such as Takeda, Daiichi Ranbaxy and others have been allowed to set operations in the country, increasing competition and consolidation.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

Competition from within

Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘ BRIC’ markets (Brazil,
Exploring MINT: Part 3 - Nigeria

At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Medical Writer - (London, Brighton or Copenhagen): Competitive

Scientific Director: Great salary and bebefits

Senior Account Manager / Account Director: Great salary and bebefits

Editorial Director – Medical Education – Oxford: Negotiable

Editor – Medical Education Agency – Bucks: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Programme Executive: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Account Manager – Med Comms – London: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Medical Writer: Great salary and benefits

Senior Medical Writer: Great salary and bebefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager or AD - Medical Communications: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Account Manager – Med Comms – Kent: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...